Alterola Biotech, Inc.
ABTI
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 273.62% | 13.41% | 277.09% | 104.61% | -72.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 287.34% | 16.68% | 35.28% | 105.12% | -73.83% |
| Operating Income | -287.34% | -16.68% | -35.28% | -105.12% | 73.83% |
| Income Before Tax | -548.70% | -46.47% | 219.74% | -235.83% | 73.83% |
| Income Tax Expenses | -- | -- | -292.30% | 3,458.62% | -- |
| Earnings from Continuing Operations | -548.70% | -46.47% | 240.83% | -275.90% | 67.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -461.53% | -46.47% | 240.83% | -275.90% | 67.17% |
| EBIT | -287.34% | -16.68% | -35.28% | -105.12% | 73.83% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -150.00% | 16.67% | 200.00% | -128.57% | 60.00% |
| Normalized Basic EPS | -200.00% | 40.00% | 50.00% | -25.00% | 75.00% |
| EPS Diluted | -150.00% | 16.67% | 200.00% | -128.57% | 60.00% |
| Normalized Diluted EPS | -200.00% | 40.00% | 50.00% | -25.00% | 75.00% |
| Average Basic Shares Outstanding | 83.41% | 77.16% | 68.61% | 56.77% | -0.86% |
| Average Diluted Shares Outstanding | 83.41% | 77.16% | 68.61% | 56.77% | -0.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |